Developments that are changing the treatment of CLL - current and future drugs

Developments that are changing the treatment of CLL - current and future drugs

VJHemOnc

3 years
641 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany, discusses the development of drugs for treatment in chronic lymphocytic leukemia (CLL). He starts by mentioning that clinicians shouldnt forget about chemotherapy or chemoimmunotherapy, which for particular patient sub-groups such as the ones with low risk genetics or mutated IGHV genes, result in very long remission after a relatively short period of treatment. Prof. Stilgenbauer mentions ibrutinib and venetoclax and furthermore, that there are second and even third generation compounds in that direction coming down the road. He also talks about PI3K inhibitors and how after some difficulty with idelalisib, they are consolidating their value for treatment. Prof. Stilgenbauer goes on to mention CAR T-cells and other immunomodulatory agents such as PD-1 and PD-L1 antibodies that he believes may hold great promise in some CLL patients, particularly those with Richters transformation which is normally very difficult to treat. Overall, he believes there is a lot to be explored and understood, which can lead to even more progress. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
Up Next Autoplay
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Category: News
10 Views
Cancer-News 11 hours
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
21 Views
SeattleCCA 4 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
11 Views
Cancer-News 4 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
8 Views
MD Anderson 5 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 5 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
6 Views
Cancer-News 5 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
25 Views
MD Anderson 5 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 5 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
8 Views
OSUCCC 5 days
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Category: Multiple Myeloma
12 Views
Cancer-News 5 days